Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics, Inc. (IPSC)
:IPSC
IPSC Stock Chart & Stats
$0.54
<$0.01(0.47%)
At close: 4:00 PM EST
$0.54
<$0.01(0.47%)
Day’s Range― - ―
52-Week Range$0.34 - $1.83
Previous CloseN/A
Volume712.78K
Average Volume (3M)790.36K
Market Cap
$49.82M
Enterprise Value-$56.18M
Total Cash (Recent Filing)$155.84M
Total Debt (Recent Filing)$51.48M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Nov 06, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding86,389,100
10 Day Avg. Volume944,475
30 Day Avg. Volume790,359
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.13
Enterprise Value/Revenue-0.49
Enterprise Value/Gross Profit-0.51
Enterprise Value/Ebitda4.33
Forecast
1Y Price Target
$4.50Price Target Upside733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's cash runway has been extended into the fourth quarter of 2027, providing financial stability for future operations.
Pipeline ExpansionCNTY-308, a next-generation CD19-directed CAR-T candidate for B-cell mediated diseases, has entered Investigational New Drug (IND)-enabling studies.
Product DevelopmentCNTY-101 is seen as a differentiated product for autoimmune disease given its strong safety profile and potentially reduced lymphodepletion requirements.
Bears Say
Clinical Trial RisksRisks include delays in advancing candidates from the company's pipeline into clinical assessment.
Enrollment ChallengesEnrollment in the CALiPSO-1 trial is still lagging, with only two patients dosed as of 2Q.
Regulatory RisksRisks include the inability to secure regulatory approval for investigational therapies, notably CNTY-101.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics, Inc.’s price range in the past 12 months?
Century Therapeutics, Inc. lowest stock price was $0.34 and its highest was $1.83 in the past 12 months.
What is Century Therapeutics, Inc.’s market cap?
Century Therapeutics, Inc.’s market cap is $49.82M.
When is Century Therapeutics, Inc.’s upcoming earnings report date?
Century Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 6 days.
How were Century Therapeutics, Inc.’s earnings last quarter?
Century Therapeutics, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.004.
Is Century Therapeutics, Inc. overvalued?
According to Wall Street analysts Century Therapeutics, Inc.’s price is currently Undervalued.
Does Century Therapeutics, Inc. pay dividends?
Century Therapeutics, Inc. does not currently pay dividends.
What is Century Therapeutics, Inc.’s EPS estimate?
Century Therapeutics, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Century Therapeutics, Inc. have?
Century Therapeutics, Inc. has 86,389,100 shares outstanding.
What happened to Century Therapeutics, Inc.’s price movement after its last earnings report?
Century Therapeutics, Inc. reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went up 1.818%.
Which hedge fund is a major shareholder of Century Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IPSC
Century Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (733.33% Upside)
$4.50 (733.33% Upside)
Hedge Fund Trend
Decreased
By 241.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $801.9 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.64%
12-Months-Change
Fundamentals
Return on Equity
-10.78%
Trailing 12-Months
Asset Growth
-31.64%
Trailing 12-Months
Company Description
Century Therapeutics, Inc.
Century Therapeutics is a biotechnology company focused on developing and commercializing innovative cell therapies for the treatment of cancer. Utilizing its proprietary induced pluripotent stem cell (iPSC) technology, Century aims to create off-the-shelf, genetically engineered immune cell therapies that can be tailored for multiple cancer types. The company operates within the sectors of regenerative medicine and oncology, with core products centered around its iPSC-derived cell therapies designed to enhance the efficacy and accessibility of cancer treatments.
IPSC Stock 12 Month Forecast
Average Price Target
$4.50
▲(733.33% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
6.36% Insiders
3.96% Mutual Funds
12.90% Other Institutional Investors
74.66% Public Companies and
Individual Investors